Dana Farber
Dana Farber
Boston, Massachusetts, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, arthropathy, connective tissue neoplasm, disease of the tendon, giant cell tumor, muscle tissue disorder, musculoskeletal system disorder, neoplasm, synovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor, diffuse type | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-25 | NCT03069469 | |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, cutaneous melanoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-04-22 | NCT06624644 | |
| Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients | graft versus host disease, immune system disorder | Recruiting | Not stated | 2025-10-20 | NCT05866302 |